Dr. Meg Mooney of the National Cancer Institute discusses new initiatives to accelerate development of cancer therapies in the era of precision medicine.
Mr. Henry Ahn of the National Science Foundation speaks on the NSF’s SBIR and STTR programs.
The largest-ever gathering in the Australian life sciences!
International BioFest 2016 will be the largest-ever gathering in Australian life sciences, with three major conferences coming together in one week in one place as one integrated network. The event will be held from 24-27 October 2016 in Melbourne by AusBiotech.
Conferences include the 17th International Biotechnology Symposium (IBS 2016), presenting the most advanced topics in biotechnology, green chemistry and its related fields; AusBiotech 2016, Australia’s national life science conference; and Australia Biotech Invest, Australia’s life science investment showcase.
Delegates from the biotechnology, biopharmaceutical, life sciences, business, investment, research, academic and health sectors will gather to celebrate Australian and international life sciences and highlight Melbourne as one of the world’s great biotechnology hubs.
FreeMind Group to discuss alternative funding
Ayal Ronen, Vice President, FreeMind Group, will be part of the panel discussing alternative funding, discussing how this flexible funding model can be used within the life science sector. Mr Ronen will be joined by Bill Best, Managing Director, On Market Book Builds, and Ross Curtin, CEO, WealthSpring International Group.
The FreeMind Group is proud to support the upcoming Trans-Pacific Health Science Dialogue!
Where: Boston, MA
When: September 28-29, 2016
Big Players Are Making Big Bets on Biopharma in Asia
- Chinese investors representing more than $5.5B are looking for Trans-Pacific investments
- Pfizer is investing $150M in a biologics plant in China
- BMS expects Opdivo sales in Japan to exceed $1B
- The Hangzhou Economic Development Area is investing $350M in a global biotech center
Can You Afford to Sit on the Sidelines?
The time to think about establishing, expanding or accelerating an Asian strategy is now. With a lineup of top Asia experts, the Trans-Pacific Health Sciences Dialogue will provide you with a solid grasp of Asian biopharma opportunities and today’s best strategies for market entry and growth. This two-day event provides critical insights you will not find at any other meeting.
For complete details and to register go to:
The FreeMind Group is a proud supporter of AdvaMed 2016
Where: Minneapolis, MN
When: October 17-19, 2016
AdvaMed 2016 is the leading MedTech Conference in North America, bringing more than 1,000 companies together for business development, capital formation, world-class educational opportunities and networking. A “must attend” event featuring a diverse attendee list that includes influential policy-makers, executives and media, AdvaMed 2016 seeks to advance the industry from key perspectives through panel sessions, executive forums and more.
Learn more about the event at www.advamed2016.com.
When: Tuesday, September 13, 2016
Where: The Westin Copley Place, Boston, MA
Attend BioSpain 2016
The FreeMind Group is a Proud Supporter of Biospain 2016
Biotech professionals from across Europe, America and Asia will converge on Biospain 2016 for a 3-day conference designed to explore innovation and biotech challenges. BIOSPAIN consists of a Trade Exhibition, an Investment Forum, a complete program of conferences and a partnering system provided by EBD Group’s partneringONE®. Highlights from the program include workshops and conferenceslike CRISPR, Big Data, New models of Pharma Innovation through acquisition, Cross Borders Venture Capital Investments, VC Investment in Diagnostics & Medical Devices, Early Stage Investment, Cancer Immunotherapy, New Diagnostic Methods, Vaccines, Alzheimer, Food and Health, Public Policies to access Innovation, Bioeconomy, Nanobiotechnology, New Oncology Therapies, among others.
BIOSPAIN Investment Forum is an international event which allows international innovative biotechnology businesses to meet with an audience of leading biotech investors.
Companies seeking international finance or partners will have the opportunity to present their business project to an audience of top corporate funds, venture capital, business angels and crowd funding platforms.
The last edition: Biospain 2014
Following the success of previous editions, Biospain 2014 hosted 200 exhibitors, more than 850 companies and institutions and over 1.850 delegates from 37 countries. One-to-one business meetings rose to 3.327 (+20%) making Biospain one of the largest business & technology transfer partnering events in the world, ranked 5th in the year 2014.